Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.

Blood reviews - 1 Nov 2022

Morschhauser Franck, Salles Gilles, Batlevi Connie Lee, Tilly Hervé, Chaidos Aristeidis, Phillips Tycel, Burke John, Melnick Ari

Abstract excerpt

Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that controls the normal biology of germinal B cells. Overexpression or mutation of EZH2 is associated with malignant transformation in a number of B-cell malignancies; thus, EZH2 inhibitors are an attractive therapeutic option for these targets. Several EZH2 inhibitors have entered clinical trials, but there remains an important question as to how...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Epigenetics and DNA Methylation

Share to Lymphoma, B-Cell

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35851487
DOI: 10.1016/j.blre.2022.100988
PMCID: PMC10372876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.PMID 35851487Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.Semantic proximity Read ↗

EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.Semantic proximity Read ↗

Overexpression of enhancer of zests homolog 2 in lymphoma.Semantic proximity Read ↗

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.